These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21782798)

  • 21. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
    Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
    Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Annexin-I overexpression is associated with tumour progression and independently predicts inferior disease-specific and metastasis-free survival in urinary bladder urothelial carcinoma.
    Li CF; Shen KH; Huang LC; Huang HY; Wang YH; Wu TF
    Pathology; 2010 Jan; 42(1):43-9. PubMed ID: 20025479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bladder squamous cell carcinoma biomarkers derived from proteomics.
    Celis JE; Wolf H; Ostergaard M
    Electrophoresis; 2000 Jun; 21(11):2115-21. PubMed ID: 10892722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
    Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
    Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
    Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
    Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R
    Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarker research and some deduction in superficial bladder cancer cells combined with corresponding stroma.
    Niu HT; Yang CM; Chen B; Dong Q
    Cancer Biomark; 2011-2012; 10(2):109-16. PubMed ID: 22430138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients.
    Chan MW; Chan LW; Tang NL; Tong JH; Lo KW; Lee TL; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
    Clin Cancer Res; 2002 Feb; 8(2):464-70. PubMed ID: 11839665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach.
    Orenes-Piñero E; Cortón M; González-Peramato P; Algaba F; Casal I; Serrano A; Sánchez-Carbayo M
    J Proteome Res; 2007 Nov; 6(11):4440-8. PubMed ID: 17902641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survivin mRNA expression in urine as a biomarker for patients with transitional cell carcinoma of bladder.
    Hou JQ; He J; Wen DG; Chen ZX; Zeng J
    Chin Med J (Engl); 2006 Jul; 119(13):1118-20. PubMed ID: 16834932
    [No Abstract]   [Full Text] [Related]  

  • 31. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
    Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
    Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteome-based diagnostics and prognosis of bladder transitional cell carcinoma.
    Wu TF; Ku WL; Tsay YG
    Expert Rev Proteomics; 2007 Oct; 4(5):639-47. PubMed ID: 17941819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
    Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
    J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological characteristics and survival outcome of arsenic related bladder cancer in taiwan.
    Chen CH; Chiou HY; Hsueh YM; Chen CJ; Yu HJ; Pu YS
    J Urol; 2009 Feb; 181(2):547-52; discussion 553. PubMed ID: 19084863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of urinary proepithelin as a potential biomarker for bladder cancer detection and prognosis in Egyptian patients.
    Selmy MA; Ibrahim GH; El Serafi TI; Ghobeish AA
    Cancer Biomark; 2010; 7(3):163-70. PubMed ID: 21263192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma].
    Li YJ; Zheng BZ; Zhou ZL
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):57-9. PubMed ID: 14981816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: a high throughput tissue microarray analysis.
    Mhawech-Fauceglia P; Fischer G; Alvarez V; Ahmed A; Herrmann FR
    BJU Int; 2007 Nov; 100(5):1182-7. PubMed ID: 17645415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and epidemiological features of patients with genitourinary tract tumour in a blackfoot disease endemic area of Taiwan.
    Tan LB; Chen KT; Guo HR
    BJU Int; 2008 Jul; 102(1):48-54. PubMed ID: 18445081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Considerations on the use of urine markers for bladder cancer.
    van Rhijn BW
    Eur Urol; 2008 May; 53(5):880-1. PubMed ID: 18222604
    [No Abstract]   [Full Text] [Related]  

  • 40. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
    el-Ahmady O; Halim AB; el-Din AG
    Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.